Tag : POLOLIKE KINASE

Abnormalities in the tumor protein 53 (TP53) gene occur in approximately 5%-10% of patients with de novo acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Despite 4 decades of research, the prognosis of patients with TP53-mutated (TP53mut) cancers remains poor as they often respond poorly to cytotoxic chemotherapy. These patients may have a median survival of 5 to 10 months, irrespective of therapies used. In a recent study, researchers from the University of Hong Kong’s Faculty of Medicine (HKUMed) identified the therapeutic potential of pololike kinase 4 (PLK4) inhibition in AML and the possible mechanisms behind its in vivo efficacy.